{
  "id": "cluster_9_doc5",
  "content": "Internal audit of CRS-229M policy impacts shows 47% denial rate for proton therapy requests in Q2 2024, compared to 12% pre-implementation. Appeals successful in 61% of cases when accompanied by genetic testing results. Network providers note particular challenges for patients with FGFR2 mutations. Memo circulated to prior authorization teams emphasizing compliance with new evidentiary standards.",
  "metadata": {
    "format": "audit_report"
  }
}